Eulalia Jiménez
AstraZeneca (Spain)(ES)
Publications by Year
Research Areas
Asthma and respiratory diseases, IL-33, ST2, and ILC Pathways, Eosinophilic Esophagitis, Respiratory and Cough-Related Research, Pharmacological Effects and Assays
Most-Cited Works
- → A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease(2023)38 cited
- → A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4(2025)36 cited
- → The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD(2021)17 cited
- → First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long‐acting Β2‐agonist(2014)17 cited
- → Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD(2016)14 cited
- → Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator(2020)13 cited
- → Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease(2024)12 cited
- → Single Doses Of LAS100977, A Novel Long Acting ²2-agonist, Show High Activity And Long Duration In Healthy Subjects(2010)10 cited
- → Análisis de las diferencias encontradas en la dilatación mediada por flujo según la terapia seguida en pacientes con enfermedad coronaria(2003)7 cited
- → Efficacy And Safety Of Single Inhaled Doses Of LAS100977, A Novel Long Acting ²2-agonist In Patients With Persistent Asthma(2010)7 cited